At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ADTX ADiTx Therapeutics
Market Closed 11-01 16:00:00 EDT
0.5299
-0.0251
-4.52%
盘后0.5290
-0.0009-0.17%
19:59 EDT
High0.5598
Low0.5101
Vol2.42M
Open0.5300
D1 Closing0.5550
Amplitude8.96%
Mkt Cap2.49M
Tradable Cap2.49M
Total Shares4.70M
T/O1.29M
T/O Rate51.56%
Tradable Shares4.70M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Aditxt announces ‘positive’ FDA feedback for Appili Therapeutics ATI-1801
BRIEF-Aditxt’S Target Acquisition Appili Therapeutics Announces Alignment With FDA On Development Requirements For ATI-1801 Topical Antiparasitic Product NDA Submission
Aditxt’s Target Acquisition Appili Therapeutics Announces Alignment With FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product Nda Submission
Press Release: Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time
Aditxt’s Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili’s Shareholder Approval
Press Release: Aditxt's Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili's Shareholder Approval
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. It is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.